Abstracts tagged "Medicare"

Abstract Number: 1048 • 2013 ACR/ARHP Annual Meeting
Generalizability Of a U.S. Rheumatoid Arthritis Registry: A Comparison Of Participants’ Vs. Non-Participants’ Characteristics
Jeffrey R. Curtis¹, Lang Chen², Huifeng Yun³, Leslie R. Harrold⁴, Jeffrey D. Greenberg⁵ and Joel M. Kremer⁶, ¹University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, ²Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵Departments of Medicine (Rheum Div) and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY, ⁶Center for Rheumatology, Albany Medical College, Albany, NY
Background/Purpose: Observational registries provide a valuable complement to clinical trials yet might suffer from limited generalizability referent to the desired population of interest. We compared…
Abstract Number: 998 • 2013 ACR/ARHP Annual Meeting
Adequacy Of Drug Coverage and Cost-Sharing For Medicare Beneficiaries With Rheumatoid Arthritis
Jinoos Yazdany¹, R. Adams Dudley², Randi Chen³ and Chien-Wen Tseng⁴, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California San Francisco Philip R. Lee Institute for Health Policy Studies, San Francisco, CA, ³Pacific Health Research and Education Institute, Honolulu, HI, ⁴Dept of Family Medicine and Community Health, University of Hawaii and Pacific Health Research and Education Institute, Honolulu, HI
Background/Purpose : Biologic and non-biologic disease-modifying anti-rheumatic drugs (DMARDs) significantly reduce pain, disability and mortality in rheumatoid arthritis (RA). We evaluated how well RA drugs…
Abstract Number: 204 • 2013 ACR/ARHP Annual Meeting
Evaluation Of Hospitalizations and Costs In Patients With Rheumatoid Arthritis In United States Medicare Population
E Alemao¹, L Wang², G Lltalien¹, O Baser³, H Yuce⁴ and M Hochberg⁵, ¹Bristol-Myers Squibb, Princeton, NJ, ²STATinMED Research, Dallas, TX, ³STATinMED Research and University of Michigan, Ann Arbor, MI, ⁴New York City College of Technology (CUNY), Brooklyn, NJ, ⁵University of Maryland, Baltimore, MD
Background/Purpose: RA-related hospitalization and surgery (e.g. total joint arthroplasty [TJA]) are important long-term outcomes in RA. While advances in treatment for RA have resulted in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].